Striving to Quit-Wisconsin Tobacco Quit Line
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01569477|
Recruitment Status : Withdrawn (Not able to recruit participants)
First Posted : April 3, 2012
Last Update Posted : December 6, 2016
|Condition or disease||Intervention/treatment||Phase|
|Smoking Cessation Smoking Nicotine Dependence||Behavioral: Incentives for abstinence and treatment engagement Behavioral: Attendance incentive||Not Applicable|
Aim 1: To determine the extent to which contingent financial "treatment incentives" (i.e., incentives for biochemical verification visits, treatment engagement, and abstinence) versus "attendance incentives" (i.e., incentives for only attending the biochemical verification visits), increase rates of smoking cessation . Participants will be BadgerCare Plus tobacco users who enroll in Wisconsin Tobacco Quit Line (WTQL) services.
Aim 2: To determine the extent to which treatment incentives vs. attendance incentives increase rates of engagement in smoking cessation treatment through the WTQL when offered to BadgerCare Plus members who smoke.
Aim 3: To determine the cost‐effectiveness of the smoking cessation program when paired with treatment incentives and when paired with attendance incentives.
Aim 4: To identify moderating and mediational effects regarding the clinical benefit of incentivized smoking treatment
Aim 5: To determine the reach of an incentivized smoking cessation treatment that depends upon primary care clinic staff, a fax‐to‐quit referral mechanism and a state quit line.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Striving to Quit: Wisconsin Tobacco Quit Line Tobacco Cessation Research|
|Study Start Date :||September 2012|
|Estimated Primary Completion Date :||March 2013|
|Actual Study Completion Date :||March 2013|
Experimental: Treatment incentives
Incentives for biochemical verification visits, treatment engagement, and abstinence
Behavioral: Incentives for abstinence and treatment engagement
Treatment incentives - incentives for biochemical verification visits, treatment engagement and abstinence
Active Comparator: Attendance incentive
Incentives for only attending the biochemical verification visits
Behavioral: Attendance incentive
Attendance Incentives - incentives for only attending the biochemical verification visits
- Abstinence from smoking [ Time Frame: Measured 6 months after enrollment at follow-up assessment ]The data will be the biochemically confirmed reports of abstinence for the past 7 days (i.e., 7-day point-prevalence abstinence)
- Engagement in treatment [ Time Frame: Measured 12 months after enrollment at follow-up assessment ]The primary analyses will compare number of calls completed
- Cost-effectiveness [ Time Frame: Measured 12 months after enrollment ]The primary analysis will contrast the incremental costs of the treatment vs. attendance conditions by computing the Incremental Cost-Effectiveness Ratio (ICER) with regard to attaining 6-month abstinence.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01569477
|Principal Investigator:||Timothy B Baker, PhD||University of Wisconsin, Madison|